Soluble Cytokine Receptor Panel (14-Plex)
Use this test to identify relevant therapy targets or investigate mechanisms of disease for inflammatory, autoimmune or neoplastic conditions.
ANALYTES / BIOMARKERS
sCD30, sEGFR, sgp130, sIL-1RI, sIL-1RII, sIL-2Rα, sIL-4R, sIL-6R, sRAGE, sTNFRI, sTNFRII, sVEGFR1, sVEGFR2, sVEGFR3
TURNAROUND-TIME (TAT)
1-5 Days
SAMPLE STABILITY
Samples collected for immune-related biomarkers are stable for approximately 1 year if kept frozen (-80˚C preferred). Samples that are left at room temperature beyond 30 minutes during sample collection or are stored at 4˚C are not stable and are not acceptable unless they are processed in BD P-100 tubes.
PROCEDURE / TECHNIQUE
Luminex® 100/200 (Addressable LASER Bead Immunoassay)
REFERENCE RANGE
Available for plasma-EDTA and CSF. See example reports below.
CLINICAL ASSOCIATIONS
Indications: Use this test to identify relevant therapy targets, determine disease mechanisms, and diagnose or monitor the following conditions associated with immune regulation, inflammation, and cancer:
- Autoimmune and Inflammatory Diseases: Assess chronic inflammatory and autoimmune diseases such as rheumatoid arthritis, systemic lupus erythematosus (SLE), and multiple sclerosis, where elevated levels of soluble receptors like sIL-1RI, sIL-1RII, sIL-2Rα, sIL-4R, and sIL-6R can indicate ongoing inflammation and immune activation.
- Chronic Inflammatory Diseases: Monitor chronic inflammatory conditions like inflammatory bowel disease (IBD), chronic obstructive pulmonary disease (COPD), and chronic kidney disease (CKD), where soluble receptors such as sIL-6R, sgp130, sRAGE, sTNFRI, and sTNFRII reflect the inflammatory state and tissue damage.
- Cancer: Evaluate tumor burden, progression, and response to therapy in various cancers including lymphoma, colorectal cancer, and lung cancer. Soluble receptors like sCD30, sEGFR, sVEGFR1, sVEGFR2, and sVEGFR3 serve as biomarkers for tumor growth, angiogenesis, and immune modulation.
- Cardiovascular Diseases: Assess cardiovascular conditions such as atherosclerosis, heart failure, and hypertension, where elevated levels of soluble receptors like sVEGFR1, sVEGFR2, sVEGFR3, and sRAGE can indicate endothelial dysfunction and vascular inflammation.
- Metabolic Disorders: Investigate metabolic syndrome, diabetes, and obesity, where soluble receptors such as sIL-6R, sTNFRI, sTNFRII, and sRAGE provide insights into the inflammatory and metabolic disturbances associated with these conditions.
- Infectious Diseases: Monitor immune response and inflammation in infectious diseases such as sepsis, HIV, and tuberculosis, where soluble receptors like sIL-1RI, sIL-1RII, sIL-2Rα, sTNFRI, and sTNFRII help assess the severity of infection and the body’s immune response.
- Pulmonary Diseases: Evaluate chronic lung diseases such as idiopathic pulmonary fibrosis (IPF) and chronic obstructive pulmonary disease (COPD), where soluble receptors like sVEGFR1, sVEGFR2, sVEGFR3, and sRAGE indicate lung tissue remodeling and inflammation.
- Allergic Diseases: Diagnose and monitor allergic conditions such as asthma, atopic dermatitis, and allergic rhinitis, where soluble receptors like sIL-4R and sIL-2Rα reflect Th2-mediated immune responses.
The interpretation of these test results should be correlated with clinical findings and other diagnostic tests. Cytokine levels can vary due to many biological, physiological, and diurnal factors; their clinical significance must be assessed by a qualified healthcare professional. This information is not intended to be used as the sole basis for diagnosis or treatment decisions.
See example reports below.
Example report – Abnormal plasma – HLH
Example report – Abnormal plasma – Paraneoplastic syndrome